Curi Bio
Curi Bio develops 3D tissue models and biosystems for drug testing, using AI to analyze safety and efficacy. The Seattle-based biotech firm has raised $30M and employs 56 people.
The growth story
Curi Bio grew from 35 to 56 employees between 2021 and 2026, raising $30M along the way, most recently a Series B in December 2025.
About
Curi Bio sells integrated platforms that combine 3D tissue disease models with biosystems and AI/ML analytics to assess drug safety, efficacy, and potency. Its tools are used in pharmaceutical R&D to inform decision-making with human-relevant data.
The company has raised $30M in funding, most recently in a Series B round in December 2025. Its 56-person workforce draws heavily from the University of Washington, with 10 employees focused on research.
Founders and leadership
Curi Bio's largest function is research, with 10 employees dedicated to this area. The company has a median tenure of 3 years, suggesting stable leadership and organizational structure.
The Curi Bio org chart
Nicholas Geisse (Chief Executive Officer) leads 25 mapped leaders with 4 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 13 (+8% YoY), Engineering 10 (+11% YoY), Business Development 10 (+25% YoY), Operations 5 (0% YoY), Information Technology 3 (0% YoY), Product Management 3 (-25% YoY).
Talent flow
Curi Bio recruits heavily from the University of Washington, with 10 alumni on staff, including 4 from its Bioengineering program. Former employees have gone on to roles at Merck, Fisher Investments, and startups like Scout and Histone Therapeutics.
Most common previous employers of Curi Bio staff: University of Washington (6), University of Washington Bioengineering (4), Kinea Bio (3), Pfizer (3), Celogics (2), Boston University (2). Former Curi Bio employees most often moved to Scout (2), Histone Therapeutics (2), Merck (1), Fisher Investments (1), Bulk Nutrients (1), Babylist (1).
Alumni worth knowing
Hiring now
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What employees say
- Compensation
- 3.40 / 5
- Career opportunities
- 4.20 / 5
- Senior management
- 3.70 / 5
- Work-life balance
- 3.90 / 5
Frequently asked
Curi Bio has 56 employees as of September 2026.
Curi Bio has raised $30M in total, most recently a Series B round in December 2025.
Curi Bio was founded in 2015 by Deok-Ho Kim, Elliot Fisher.
Nicholas Geisse (Chief Executive Officer) sits at the top of Curi Bio's reporting structure, with 4 direct reports.
The most common previous employers of current Curi Bio staff are University of Washington (6 people), University of Washington Bioengineering (4 people), Kinea Bio (3 people).
Former Curi Bio employees most often move to Scout (2), Histone Therapeutics (2), Merck (1).
Curi Bio has about 13 people in Research, up 8% over the past year, as of September 2026.
Curi Bio has about 10 people in Engineering, up 11% over the past year, as of September 2026.
Computed from 42 current and 40 former Curi Bio profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.